

# Blood Cancer Drugs Market - 2022

<https://marketpublishers.com/r/B7A71AE004D7EN.html>

Date: June 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: B7A71AE004D7EN

## Abstracts

The Blood Cancer Drugs Market was valued at USD 63 billion in 2022 and is anticipated to reach by , at a CAGR of 0.078 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Blood Cancer Drugs Market.

This report delivers a comprehensive overview of the Blood Cancer Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Blood Cancer Drugs Market. The Blood Cancer Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

Blood Cancer Drugs Market Scope:

By Cancer Type

Leukemia

Myeloma

Non-Hodgkin Lymphoma

## Hodgkin Lymphoma

### By Therapy Type

Chemotherapy

Radiation Therapy

Immunotherapy

Targeted Therapy

Others

### By Route of Administration

Oral

Parenteral

Others

### By End user

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Others

### Key Players

Amgen Inc.

AstraZeneca Plc

Takeda Pharmaceutical Company Ltd

Bayer AG

Celgene Corporation

Eli Lilly

Bristol-Myers Squibb Company

Gilead Sciences Inc.

Daiichi Sankyo Company Ltd

UCB SA(LIST NOT EXHAUSTIVE)

## Major Highlights

This report delivers a comprehensive overview of the Blood Cancer Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Blood Cancer Drugs Market. The Blood Cancer Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Snippet by Cancer Type
- 3.2. Snippet by Therapy Type
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by End user
- 3.5. Snippet by Region

### **4. DYNAMICS**

- 4.1. Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. Increasing prevalence of blood cancers
    - 4.1.1.2. XX
  - 4.1.2. Restraints
    - 4.1.2.1. High cost of treatment
    - 4.1.2.2. Side effects associated with treatment
    - 4.1.2.3. XX
  - 4.1.3. Opportunity
    - 4.1.3.1. Advancements in cancer research
  - 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis

### **6. COVID-19 ANALYSIS**

- 6.1. Analysis of COVID-19
  - 6.1.1. Scenario Before COVID-19
  - 6.1.2. Scenario During COVID-19
  - 6.1.3. Post COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturer's Strategic Initiatives
- 6.6. Conclusion

## **7. BY CANCER TYPE**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  - 7.1.2. Market Attractiveness Index, By Cancer Type
- 7.2. Leukemia\*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Myeloma
- 7.4. Non-Hodgkin Lymphoma
- 7.5. Hodgkin Lymphoma

## **8. BY THERAPY TYPE**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  - 8.1.2. Market Attractiveness Index, By Therapy Type
- 8.2. Chemotherapy\*
  - 8.2.1. Introduction
  - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Radiation Therapy
- 8.4. Immunotherapy
- 8.5. Targeted Therapy
- 8.6. Others

## **9. BY ROUTE OF ADMINISTRATION**

- 9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.1.2. Market Attractiveness Index, By Route of Administration

9.2. Oral\*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Parenteral

9.4. Others

## **10. BY END USER**

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

10.1.2. Market Attractiveness Index, By End user

10.2. Hospitals\*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. Specialty Clinics

10.4. Ambulatory Surgical Centers

10.5. Others

## **11. BY REGION**

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type

11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.2.7.1. The U.S.

11.2.7.2. Canada

11.2.7.3. Mexico

11.3. Europe

- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. The UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
- 11.4. South America
  - 11.4.1. Introduction
  - 11.4.2. Key Region-Specific Dynamics
  - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  - 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
  - 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.4.7.1. Brazil
    - 11.4.7.2. Argentina
    - 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
  - 11.5.1. Introduction
  - 11.5.2. Key Region-Specific Dynamics
  - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  - 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
  - 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.5.7.1. China
    - 11.5.7.2. India
    - 11.5.7.3. Japan
    - 11.5.7.4. Australia

11.5.7.5. Rest of Asia-Pacific

11.6. Middle East and Africa

11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type

11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

## **12. COMPETITIVE LANDSCAPE**

12.1. Competitive Scenario

12.2. Market Positioning/Share Analysis

12.3. Mergers and Acquisitions Analysis

## **13. COMPANY PROFILES**

13.1. Amgen Inc.\*

13.1.1. Company Overview

13.1.2. Product Portfolio and Description

13.1.3. Financial Overview

13.1.4. Key Developments

13.2. AstraZeneca Plc

13.3. Takeda Pharmaceutical Company Ltd

13.4. Bayer AG

13.5. Celgene Corporation

13.6. Eli Lilly

13.7. Bristol-Myers Squibb Company

13.8. Gilead Sciences Inc.

13.9. Daiichi Sankyo Company Ltd

13.10. UCB SA(\*LIST NOT EXHAUSTIVE)

## **14. APPENDIX**

14.1. About Us and Services

14.2. Contact Us

## I would like to order

Product name: Blood Cancer Drugs Market - 2022

Product link: <https://marketpublishers.com/r/B7A71AE004D7EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B7A71AE004D7EN.html>